Abetimus

From Wikipedia, the free encyclopedia

Abetimus
Systematic (IUPAC) name
?
Identifiers
CAS number	169147-32-4
ATC code	L04AA22
PubChem	?
Chemical data
Formula	?
Mol. mass	?
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Abetimus is an immunosuppressant.^[1] It is a synthetic molecule called a toleragen. It is made of four double-stranded oligodeoxyribonucleotides that are attached to a carrier platform and are designed to block specific B-cell anti double stranded DNA antibodies. It may also complex anti dsDNA antibodies together, therefore disabling them. This way Abetimus is supposed to help treat Systemic Lupus Erythematosus and specifically nephritis.

[edit] References

^ &Na;, (2003). "Abetimus: Abetimus sodium, LJP 394". BioDrugs 17 (3): 212–5. doi:10.2165/00063030-200317030-00009. PMID 12749759.

Immunomodulators: Immunosuppressive drugs / Immunosuppressants (L04)

Intracellular
(signal initiation)

Antimetabolites	purine synthesis inhibitor: Azathioprine · Mycophenolic acid pyrimidine synthesis inhibitor: Leflunomide · Teriflunomide antifolate: Methotrexate

Macrolides/ other IL-2 inhibitors	FKBP/Cyclophilin/Calcineurin: Tacrolimus · Ciclosporin · Pimecrolimus Abetimus · Gusperimus

TNF-α inhibitor	Thalidomide · Lenalidomide

Intracellular
(signal reception)

IL-1 receptor antagonists	Anakinra

mTOR	Sirolimus · Deforolimus · Everolimus · Temsirolimus · Zotarolimus · Biolimus A9

Extracellular

Antibodies

Monoclonal

Serum target (noncellular)	Complement component 5 (Eculizumab) · TNFs (Infliximab, Adalimumab, Certolizumab pegol, Afelimomab, Golimumab) · Interleukin 5 (Mepolizumab) · Immunoglobulin E (Omalizumab) · BAYX (Nerelimomab) Interferon (Faralimomab) IL-6 (Elsilimomab) IL-12 and IL-13 (Lebrikizumab, Ustekinumab)

Cellular target	CD3 (Muromonab-CD3, Otelixizumab, Teplizumab, Visilizumab) · CD4 (Clenoliximab, Keliximab, Zanolimumab) · CD11a (Efalizumab) · CD18 (Erlizumab) · CD20 (Afutuzumab, Ocrelizumab, Pascolizumab) · CD23 (Lumiliximab) · CD40 (Teneliximab, Toralizumab) · CD62L/L-selectin (Aselizumab) · CD80 (Galiximab) · CD147/Basigin (Gavilimomab) · CD154 (Ruplizumab) BLyS (Belimumab) · CTLA-4 (Ipilimumab, Tremelimumab) · CAT (Bertilimumab, Lerdelimumab, Metelimumab) · Integrin (Natalizumab) · Interleukin-6 receptor (Tocilizumab) · LFA-1 (Odulimomab) IL-2 receptor/CD25 (Basiliximab, Daclizumab, Inolimomab) T-lymphocyte (Zolimomab aritox)

Unsorted	Atorolimumab, Cedelizumab, Dorlixizumab, Fontolizumab, Gantenerumab, Gomiliximab, Maslimomab, Morolimumab, Pexelizumab, Reslizumab, Rovelizumab, Siplizumab, Talizumab, Telimomab aritox, Vapaliximab, Vepalimomab